Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially considering that Adcetris has been on the market for six years. Fortunately, sales should accelerate from here with an expanded approval under review at the FDA and another one ready to be submitted soon.
Metric
Q3 2017
Source: Fool.com
Bristol-Myers Squibb Stock
€37.53
0.620%
Our community is currently high on Bristol-Myers Squibb with 11 Buy predictions and 3 Sell predictions.
With a target price of 70 € there is a hugely positive potential of 86.52% for Bristol-Myers Squibb compared to the current price of 37.53 €.
